TheraRadar
Landscape → Oncology

Breast Cancer Clinical Trial Landscape

Data updated: May 20, 2026

3,886 clinical trials tracked since 2008

Breast cancer is a disease in which cells in the breast grow uncontrollably. It is the most common cancer diagnosed in women in the United States. Since 2008, 3,869 breast cancer clinical trials have been registered, with 1,493 trials currently active, meaning they are recruiting, enrolling, or active but not recruiting patients. The majority of active trials are in Phase 2, with 893 trials, compared to 321 in Phase 3 and 54 in Phase 4. Phase 1 trials also represent a significant portion of the active pipeline, with 421 trials underway. AstraZeneca leads industry sponsorship of active breast cancer trials with 29, followed by Roche with 24, Pfizer with 16, Novartis with 11, and Shandong Suncadia Medicine Co., Ltd. with 10 active trials. The high number of Phase 2 trials suggests a strong focus on evaluating the efficacy and safety of new treatments in mid-stage development.

1502 active
/
3886 total (since 2008)
420
Phase 1 Active
1280 total
896
Phase 2 Active
2252 total
323
Phase 3 Active
697 total
58
Phase 4 Active
158 total

Top Industry Sponsors

Sorted by active Active Done Failed
AstraZeneca 29 25 3
Roche 24 82 19
Pfizer 16 15 11
Novartis 11 52 12
Shandong Suncadia Medicine Co., Ltd. 10 1 0

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT06058377 RECRUITING
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
National Cancer Institute (NCI) n=3,680
NCT04622319 ACTIVE NOT RECRUITING
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
Daiichi Sankyo n=1,600
NCT06377852 RECRUITING
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
American Society of Clinical Oncology n=500
NCT02954874 ACTIVE NOT RECRUITING
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI) n=1,155
NCT03488693 RECRUITING
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Canadian Cancer Trials Group n=2,140

+ 692 more Phase 3 trials — see full database below

Breast Cancer — Trials Started by Year (last 10 years)

2016
196
2017
196
2018
166
2019
179
2020
214
2021
212
2022
213
2023
263
2024
275
2025
314
2026
170

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

AstraZeneca
57
Roche
125
Pfizer
42
Novartis
75
Shandong Suncadia Medicine Co., Ltd.
11
Sichuan Baili Pharmaceutical Co., Ltd.
11
Jiangsu HengRui Medicine Co., Ltd.
21
Eli Lilly
30
Daiichi Sankyo
11
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
6

Active Trials by Phase

Phase 1
420
Phase 2
896
Phase 3
323
Phase 4
58

Enrollment Size Distribution

1-50
1,588
51-200
1,338
201-500
476
501-1k
169
1k+
127

All Industry Sponsors

Sorted by active Active Done Failed
AstraZeneca 29 25 3
Roche 24 82 19
Pfizer 16 15 11
Novartis 11 52 12
Shandong Suncadia Medicine Co., Ltd. 10 1 0
Sichuan Baili Pharmaceutical Co., Ltd. 10 0 1
Jiangsu HengRui Medicine Co., Ltd. 9 8 4
Eli Lilly 8 19 3
Daiichi Sankyo 7 2 2
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 6 0 0
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 5 5 1
Olema Pharmaceuticals, Inc. 5 1 0
Shanghai Henlius Biotech 5 1 0
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 5 0 1
MediLink Therapeutics (Suzhou) Co., Ltd. 5 0 0
NCT06058377 RECRUITING
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
National Cancer Institute (NCI) n=3,680
NCT04622319 ACTIVE NOT RECRUITING
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
Daiichi Sankyo n=1,600
NCT06377852 RECRUITING
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
American Society of Clinical Oncology n=500
NCT02954874 ACTIVE NOT RECRUITING
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI) n=1,155
NCT07391774 NOT YET RECRUITING
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
National Cancer Institute (NCI) n=1,978
NCT03488693 RECRUITING
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Canadian Cancer Trials Group n=2,140
NCT07205822 RECRUITING
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
AstraZeneca n=100
NCT02445391 ACTIVE NOT RECRUITING
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
ECOG-ACRIN Cancer Research Group n=415
NCT04739761 ACTIVE NOT RECRUITING
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
AstraZeneca n=506
NCT05379153 RECRUITING
Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial
Alliance for Clinical Trials in Oncology n=250
NCT04055493 ACTIVE NOT RECRUITING
Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC
West German Study Group n=1,684
NCT07578116 NOT YET RECRUITING
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
SWOG Cancer Research Network n=562
NCT05827081 RECRUITING
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Novartis Pharmaceuticals n=1,400
NCT06876714 RECRUITING
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Alliance for Clinical Trials in Oncology n=1,524
NCT07071337 RECRUITING
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. n=430
NCT05812807 RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Alliance for Clinical Trials in Oncology n=1,295
NCT05774951 RECRUITING
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
AstraZeneca n=4,300
NCT06081959 RECRUITING
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. n=376
NCT06982521 RECRUITING
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Relay Therapeutics, Inc. n=540
NCT06507618 RECRUITING
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
University of Virginia n=354
NCT06500481 RECRUITING
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
NRG Oncology n=115
NCT05879926 RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NRG Oncology n=3,960
NCT04175210 ACTIVE NOT RECRUITING
Prospective Randomized Study of Accelerated Radiation Therapy (PRART)
Weill Medical College of Cornell University n=397
NCT05587296 ACTIVE NOT RECRUITING
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
Bayer n=474
NCT05646862 ACTIVE NOT RECRUITING
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Hoffmann-La Roche n=420
NCT07062965 RECRUITING
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer n=400
NCT07242352 RECRUITING
Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
West German Study Group n=1,520
NCT02032823 ACTIVE NOT RECRUITING
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
AstraZeneca n=1,837
NCT02488967 ACTIVE NOT RECRUITING
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NRG Oncology n=782
NCT02918084 ACTIVE NOT RECRUITING
CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy n=1,000
NCT07178730 NOT YET RECRUITING
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
West German Study Group n=765
NCT01202851 ACTIVE NOT RECRUITING
Relaxation for Women With Breast Cancer Undergoing Radiotherapy
M.D. Anderson Cancer Center n=681
NCT05104866 ACTIVE NOT RECRUITING
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
AstraZeneca n=732
NCT06065748 RECRUITING
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Hoffmann-La Roche n=1,050
NCT01272037 ACTIVE NOT RECRUITING
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
National Cancer Institute (NCI) n=5,018
NCT06500455 RECRUITING
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology n=269
NCT06790693 RECRUITING
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche n=450
NCT05894239 RECRUITING
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche n=230
NCT04305496 ACTIVE NOT RECRUITING
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
AstraZeneca n=818
NCT02115282 ACTIVE NOT RECRUITING
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
National Cancer Institute (NCI) n=608
NCT05306340 ACTIVE NOT RECRUITING
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Genentech, Inc. n=373
NCT06103864 RECRUITING
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
AstraZeneca n=625
NCT07554573 NOT YET RECRUITING
Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT)
NRG Oncology n=5,270
NCT01905046 ACTIVE NOT RECRUITING
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
Alliance for Clinical Trials in Oncology n=86
NCT07400523 RECRUITING
Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=446
NCT03155997 ACTIVE NOT RECRUITING
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
Eli Lilly and Company n=5,637
NCT06492616 RECRUITING
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Stemline Therapeutics, Inc. n=4,220
NCT06889688 RECRUITING
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=246
NCT04852887 RECRUITING
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NRG Oncology n=1,670
NCT07541079 NOT YET RECRUITING
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
Genentech, Inc. n=300
NCT06748222 RECRUITING
E-Mindfulness Approaches for Living After Breast Cancer
NRG Oncology n=402
NCT06062810 ACTIVE NOT RECRUITING
Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair n=600
NCT07543536 NOT YET RECRUITING
Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer
Sun Yat-sen University n=132
NCT03927027 ACTIVE NOT RECRUITING
Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection
Alliance for Clinical Trials in Oncology n=534
NCT05696626 RECRUITING
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
LeonaBio n=500
NCT04862663 RECRUITING
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
AstraZeneca n=895
NCT05132582 ACTIVE NOT RECRUITING
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer n=654
NCT06195709 RECRUITING
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
Institut Curie n=300
NCT05780567 ACTIVE NOT RECRUITING
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=1,946
NCT07085767 RECRUITING
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Olema Pharmaceuticals, Inc. n=1,000
NCT04421963 ACTIVE NOT RECRUITING
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
AstraZeneca n=185
NCT05296798 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Hoffmann-La Roche n=922
NCT07528716 NOT YET RECRUITING
Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy
Fudan University n=280
NCT06380751 RECRUITING
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
AstraZeneca n=500
NCT04650581 ACTIVE NOT RECRUITING
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor
Canadian Cancer Trials Group n=250
NCT03820830 ACTIVE NOT RECRUITING
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer
ETOP IBCSG Partners Foundation n=405
NCT06764186 ACTIVE NOT RECRUITING
A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain
AstraZeneca n=101
NCT05950945 RECRUITING
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Daiichi Sankyo n=250
NCT05038735 ACTIVE NOT RECRUITING
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Novartis Pharmaceuticals n=234
NCT06072612 RECRUITING
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
BriaCell Therapeutics Corporation n=404
NCT04715958 RECRUITING
SHAPE Neoadjuvant Chemotherapy Response
Kibo Nam n=200
NCT06382948 RECRUITING
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
MedSIR n=240
NCT04851613 ACTIVE NOT RECRUITING
Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Laekna Limited n=256
NCT04208178 ACTIVE NOT RECRUITING
Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
Novartis Pharmaceuticals n=19
NCT07432178 NOT YET RECRUITING
CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）
Fudan University n=2,288
NCT06112379 ACTIVE NOT RECRUITING
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
AstraZeneca n=1,902
NCT07340658 NOT YET RECRUITING
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
Rovi Pharmaceuticals Laboratories n=300
NCT03701334 ACTIVE NOT RECRUITING
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
Novartis Pharmaceuticals n=5,101
NCT03315364 ACTIVE NOT RECRUITING
Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy
Daehwa Pharmaceutical Co., Ltd. n=549
NCT07502820 NOT YET RECRUITING
The POWER Trial: Personalised Dose Optimisation With Adjuvant Tamoxifen Therapy in Breast cancER
Karolinska Institutet n=1,100
NCT06954961 RECRUITING
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
InventisBio Co., Ltd n=640
NCT06635447 ACTIVE NOT RECRUITING
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
AstraZeneca n=258
NCT07354022 RECRUITING
A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.
Shandong Suncadia Medicine Co., Ltd. n=912
NCT05072314 RECRUITING
Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial
Monash University n=4,300
NCT07106632 NOT YET RECRUITING
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
UNICANCER n=3,380
NCT07294508 RECRUITING
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
Shanghai Henlius Biotech n=706
NCT07486687 NOT YET RECRUITING
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy
The Netherlands Cancer Institute n=1,000
NCT05232916 RECRUITING
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Greenwich LifeSciences, Inc. n=750
NCT07483996 NOT YET RECRUITING
Cryoablation Versus Lumpectomy in Early-Stage Breast Cancer
Franciscus Gasthuis & Vlietland (Hospital) n=938
NCT07349069 RECRUITING
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer
Shandong Suncadia Medicine Co., Ltd. n=4,800
NCT02089100 ACTIVE NOT RECRUITING
Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris n=154
NCT05654623 ACTIVE NOT RECRUITING
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
Pfizer n=624
NCT05629585 ACTIVE NOT RECRUITING
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
AstraZeneca n=1,174
NCT04191499 ACTIVE NOT RECRUITING
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche n=325
NCT07237256 RECRUITING
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
UNICANCER n=3,902
NCT05766891 RECRUITING
Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery
M.D. Anderson Cancer Center n=225
NCT06016738 RECRUITING
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Olema Pharmaceuticals, Inc. n=510
NCT07467330 RECRUITING
Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment
Fujian Cancer Hospital n=258
NCT06057610 ACTIVE NOT RECRUITING
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. n=868
NCT07461454 NOT YET RECRUITING
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd. n=376
NCT01349322 ACTIVE NOT RECRUITING
Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery
Radiation Therapy Oncology Group n=2,354
NCT06018337 ACTIVE NOT RECRUITING
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
DualityBio Inc. n=541
NCT04494425 ACTIVE NOT RECRUITING
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
AstraZeneca n=866
NCT04873362 ACTIVE NOT RECRUITING
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Hoffmann-La Roche n=1,188
NCT06760637 ACTIVE NOT RECRUITING
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Pfizer n=1,035
NCT04241341 ACTIVE NOT RECRUITING
Does Immediate Lymphatic Reconstruction Decrease the Risk of Lymphedema After Axillary Lymph Node Dissection
Memorial Sloan Kettering Cancer Center n=180
NCT07281833 RECRUITING
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
West German Study Group n=250
NCT03414970 ACTIVE NOT RECRUITING
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
Alliance for Clinical Trials in Oncology n=898
NCT05113251 ACTIVE NOT RECRUITING
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
AstraZeneca n=927
NCT04784715 ACTIVE NOT RECRUITING
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
AstraZeneca n=1,157
NCT04546009 ACTIVE NOT RECRUITING
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
Hoffmann-La Roche n=992
NCT04961996 ACTIVE NOT RECRUITING
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Hoffmann-La Roche n=4,170
NCT05316324 ACTIVE NOT RECRUITING
A Study of the Use of Acellular Dermal Matrix for Breast Reconstruction
Memorial Sloan Kettering Cancer Center n=353
NCT07410169 NOT YET RECRUITING
Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy
Guangdong Provincial People's Hospital n=160
NCT02947685 ACTIVE NOT RECRUITING
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
Alliance Foundation Trials, LLC. n=518
NCT07406542 NOT YET RECRUITING
A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd. n=400
NCT07407517 NOT YET RECRUITING
Adjuvant Intensification for LAR
Fudan University n=904
NCT06135714 RECRUITING
Metastasis-directed Therapy for Oligometastases of Breast Cancer
Tokyo Medical and Dental University n=340
NCT07385365 NOT YET RECRUITING
A Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=3,142
NCT01674140 ACTIVE NOT RECRUITING
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
SWOG Cancer Research Network n=1,939
NCT05909397 ACTIVE NOT RECRUITING
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
Pfizer n=59
NCT02513394 ACTIVE NOT RECRUITING
PALbociclib CoLlaborative Adjuvant Study
Alliance Foundation Trials, LLC. n=5,796
NCT05501886 ACTIVE NOT RECRUITING
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Celcuity Inc n=701
NCT04639986 ACTIVE NOT RECRUITING
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Gilead Sciences n=331
NCT07393321 NOT YET RECRUITING
A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer
Nanjing Chia-tai Tianqing Pharmaceutical n=210
NCT06757634 RECRUITING
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity Inc n=1,180
NCT02763566 ACTIVE NOT RECRUITING
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
Eli Lilly and Company n=463
NCT07386938 ACTIVE NOT RECRUITING
A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer
R-Pharm n=246
NCT07382687 NOT YET RECRUITING
Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype
Fudan University n=248
NCT02246621 ACTIVE NOT RECRUITING
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
Eli Lilly and Company n=493
NCT07047365 RECRUITING
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. n=416
NCT05439005 RECRUITING
Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study.
Institut Curie n=158
NCT06144944 ACTIVE NOT RECRUITING
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=160
NCT07371910 ACTIVE NOT RECRUITING
Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=200
NCT07372144 NOT YET RECRUITING
Creatine and Cognitive Health in Patients With Early-stage Breast Cancer During and After Chemotherapy Treatment
D'Or Institute for Research and Education n=227
NCT06704945 RECRUITING
No Axillary Surgical Treatment in Clinically Lymph Node Negative Patients on Ultrasonography After Neoadjuvant Chemotherapy
Seoul National University Hospital n=464
NCT07373782 RECRUITING
Continuous Positive Airway Pressure (CPAP) Assisted Radiotherapy in Breast Cancer
Universitaire Ziekenhuizen KU Leuven n=53
NCT05374512 ACTIVE NOT RECRUITING
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
AstraZeneca n=644
NCT07366840 NOT YET RECRUITING
RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure
Fudan University n=268
NCT07024173 RECRUITING
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd. n=240
NCT07362914 RECRUITING
Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions
Fudan University n=182
NCT06763328 RECRUITING
Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy
City of Hope Medical Center n=200
NCT07357298 RECRUITING
Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute n=156
NCT01953588 ACTIVE NOT RECRUITING
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Alliance for Clinical Trials in Oncology n=1,473
NCT06957886 RECRUITING
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. n=566
NCT05909332 RECRUITING
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
Fudan University n=764
NCT07019363 RECRUITING
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
Fudan University n=1,903
NCT07350928 RECRUITING
Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake Status
Tianjin Medical University Cancer Institute and Hospital n=394
NCT04443413 ACTIVE NOT RECRUITING
Phase III Study of 5tx vs 15tx of RT (X-rays or Protons) Including RNI in Breast Cancer Patients
Mayo Clinic n=146
NCT04584853 ACTIVE NOT RECRUITING
PreOperative Endocrine Therapy for Individualised Care With Abemaciclib
Institute of Cancer Research, United Kingdom n=123
NCT05860465 RECRUITING
Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd n=254
NCT04906395 ACTIVE NOT RECRUITING
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
Tolmar Inc. n=250
NCT04320979 ACTIVE NOT RECRUITING
Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=2,400
NCT05645536 ENROLLING BY INVITATION
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Tolmar Inc. n=250
NCT04290793 ACTIVE NOT RECRUITING
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
Hebei Medical University Fourth Hospital n=113
NCT07207070 RECRUITING
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
Risen (Suzhou) Pharma Tech Co., Ltd. n=312
NCT07310758 RECRUITING
Contrast-enhanced Ultrasound for Sentinel Node Detection
The Netherlands Cancer Institute n=91
NCT02051218 ACTIVE NOT RECRUITING
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
Swiss Cancer Institute n=1,380
NCT05774678 RECRUITING
Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation
M.D. Anderson Cancer Center n=126
NCT07294534 NOT YET RECRUITING
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer
Shanghai Henlius Biotech n=817
NCT07269691 NOT YET RECRUITING
RaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer
Pengfei Qiu n=194
NCT06787118 NOT YET RECRUITING
Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris n=130
NCT06781996 RECRUITING
A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris n=180
NCT02810743 ACTIVE NOT RECRUITING
Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer
The Netherlands Cancer Institute n=174
NCT04193059 ACTIVE NOT RECRUITING
Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer
Fudan University n=1,560
NCT04514419 ACTIVE NOT RECRUITING
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
BioRay Pharmaceutical Co., Ltd. n=408
NCT04565054 ACTIVE NOT RECRUITING
Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC
West German Study Group n=1,260
NCT05910398 RECRUITING
Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer
RenJi Hospital n=488
NCT04874038 RECRUITING
Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN)
University Health Network, Toronto n=1,602
NCT06144164 RECRUITING
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
Memorial Sloan Kettering Cancer Center n=285
NCT05929768 RECRUITING
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
SWOG Cancer Research Network n=2,400
NCT04457596 ACTIVE NOT RECRUITING
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Alliance for Clinical Trials in Oncology n=1,056
NCT03529110 ACTIVE NOT RECRUITING
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
Daiichi Sankyo n=524
NCT03418961 RECRUITING
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
SWOG Cancer Research Network n=491
NCT07213206 NOT YET RECRUITING
CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer
Fudan University n=1,500
NCT03734029 ACTIVE NOT RECRUITING
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Daiichi Sankyo n=557
NCT05840211 ACTIVE NOT RECRUITING
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
Gilead Sciences n=654
NCT07166042 RECRUITING
Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies
University of Utah n=34
NCT06449027 ACTIVE NOT RECRUITING
Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.
Changchun GeneScience Pharmaceutical Co., Ltd. n=211
NCT07190443 RECRUITING
Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)
Japanese Foundation for Cancer Research n=290
NCT05760612 RECRUITING
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=300
NCT06680921 RECRUITING
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Jiangsu Simcere Pharmaceutical Co., Ltd. n=460
NCT04335669 ACTIVE NOT RECRUITING
NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
Lund University Hospital n=325
NCT06079983 RECRUITING
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Jiangsu Alphamab Biopharmaceuticals Co., Ltd n=400
NCT04254263 RECRUITING
Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
RenJi Hospital n=316
NCT05856773 RECRUITING
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
Proton Collaborative Group n=276
NCT04379570 ACTIVE NOT RECRUITING
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
Alliance for Clinical Trials in Oncology n=1,167
NCT05063786 ACTIVE NOT RECRUITING
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
Spanish Breast Cancer Research Group n=27
NCT07153757 NOT YET RECRUITING
De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial
Fudan University n=2,934
NCT04134598 ACTIVE NOT RECRUITING
ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer
Azienda Ospedaliero-Universitaria Careggi n=926
NCT03351348 RECRUITING
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
Memorial Sloan Kettering Cancer Center n=165
NCT05424835 ACTIVE NOT RECRUITING
A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Jiangsu HengRui Medicine Co., Ltd. n=381
NCT05512364 RECRUITING
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
European Organisation for Research and Treatment of Cancer - EORTC n=220
NCT05744687 RECRUITING
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd n=374
NCT06255392 RECRUITING
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=200
NCT07008976 RECRUITING
Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. n=246
NCT06960707 RECRUITING
Two Versus One Week Breast Radiotherapy (RT)
Weill Medical College of Cornell University n=400
NCT05703178 RECRUITING
Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
Northwestern University n=452
NCT07084519 NOT YET RECRUITING
Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=190
NCT05802225 ACTIVE NOT RECRUITING
Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer
Biocad n=398
NCT05257395 ACTIVE NOT RECRUITING
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
Xuanzhu Biopharmaceutical Co., Ltd. n=397
NCT07066280 RECRUITING
Modulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=326
NCT07061717 NOT YET RECRUITING
Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=474
NCT03725059 ACTIVE NOT RECRUITING
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
Merck Sharp & Dohme LLC n=1,240
NCT06835400 NOT YET RECRUITING
Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer
Health Hope Pharma n=340
NCT07057427 RECRUITING
Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
Henan Cancer Hospital n=812
NCT05796973 RECRUITING
Measuring Oncological Value of Exercise and Statin
Tampere University Hospital n=240
NCT06839001 RECRUITING
CRYoablation for Small Tumors As Local Treatment - SIX Trial
Hospital do Coracao n=750
NCT01564056 ACTIVE NOT RECRUITING
Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment
UNICANCER n=1,989
NCT07003074 RECRUITING
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. n=642
NCT06434077 NOT YET RECRUITING
Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer
S.LAB (SOLOWAYS) n=60
NCT05952557 RECRUITING
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
AstraZeneca n=5,500
NCT06383767 RECRUITING
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Qilu Pharmaceutical Co., Ltd. n=378
NCT07021261 NOT YET RECRUITING
Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients
Fudan University n=440
NCT05552001 RECRUITING
Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer
UNICANCER n=96
NCT02804815 ACTIVE NOT RECRUITING
Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
University College, London n=11,000
NCT05346224 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
Shanghai Henlius Biotech n=900
NCT07005557 NOT YET RECRUITING
Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer
Fudan University n=1,244
NCT06998108 RECRUITING
Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
BeBetter Med Inc n=330
NCT06996093 NOT YET RECRUITING
Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor
Fudan University n=2,508
NCT05838066 RECRUITING
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
Shanghai JMT-Bio Inc. n=880
NCT06915857 RECRUITING
Topical Betamethasone Versus Moisturizer in Preventing Radiation Dermatitis in Large-Breasted Patients Treated in the Prone Position
Sunnybrook Health Sciences Centre n=276
NCT03201861 RECRUITING
Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women
RenJi Hospital n=762
NCT01805271 ACTIVE NOT RECRUITING
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
UNICANCER n=1,278
NCT04261244 RECRUITING
NeoRad Breast Cancer Study
Bielefeld University n=1,826
NCT06958627 RECRUITING
The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=964
NCT06126640 RECRUITING
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Jiangsu HengRui Medicine Co., Ltd. n=1,600
NCT06643585 RECRUITING
A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse
Prof. Wolfgang Janni n=180
NCT05207709 ACTIVE NOT RECRUITING
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
SOLTI Breast Cancer Research Group n=456
NCT04989504 ACTIVE NOT RECRUITING
Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy
Alliance for Clinical Trials in Oncology n=216
NCT06947330 RECRUITING
Comparison Between Erector Spinae Plane Block Versus Serratus Anterior Plane Block Regarding Analgesia Post Modified Radical Mastectomy
Kholoud Usama n=100
NCT06313983 RECRUITING
A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer
Tianjin Hemay Pharmaceutical Co., Ltd n=339
NCT06223698 NOT YET RECRUITING
Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer
Region Örebro County n=3,832
NCT05288777 RECRUITING
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
University of Virginia n=45
NCT06929325 NOT YET RECRUITING
Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=312
NCT06926543 RECRUITING
Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy
Dr. Tabassum Wadasadawala n=858
NCT01785420 RECRUITING
Pre Operative Trastuzumab in Operable Breast Cancer
Dr Rajendra A. Badwe n=1,100
NCT01916317 ACTIVE NOT RECRUITING
Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer
Tata Memorial Hospital n=1,600
NCT04711109 ACTIVE NOT RECRUITING
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
Alliance for Clinical Trials in Oncology n=300
NCT06846437 RECRUITING
JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
Shanghai JMT-Bio Inc. n=228
NCT06857305 ENROLLING BY INVITATION
Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial
Ma Fei，MD n=192
NCT06611891 RECRUITING
Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer
University Hospital, Grenoble n=25
NCT02625441 ACTIVE NOT RECRUITING
Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer
Helsinki University Central Hospital n=516
NCT06811220 NOT YET RECRUITING
The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients
Alexandria University n=140
NCT06106529 RECRUITING
REDucing Hot FLASHes in Women Using Endocrine Therapy.
Reinier de Graaf Groep n=260
NCT06774885 NOT YET RECRUITING
ROLE OF FOLIC ACID IN THE MANAGEMENT OF ADJUVANT ENDOCRINE THERAPY-INDUCED HOT FLASHES IN BREAST CANCER PATIENTS
Future University in Egypt n=120
NCT02750826 ACTIVE NOT RECRUITING
Breast Cancer WEight Loss Study (BWEL Study)
Alliance for Clinical Trials in Oncology n=3,177
NCT01901094 ACTIVE NOT RECRUITING
Comparison of Axillary Lymph Node Dissection with Axillary Radiation for Patients with Node-Positive Breast Cancer Treated with Chemotherapy
Alliance for Clinical Trials in Oncology n=2,012
NCT06769919 NOT YET RECRUITING
A Randomized Controlled Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined with Systemic Therapy for Early-stage Breast Cancer
Xijing Hospital n=340
NCT06757621 RECRUITING
Hypofractionated Postoperative Regional Nodal Irradiation for Patients With Intermediate-risk Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=3,142
NCT05747794 ACTIVE NOT RECRUITING
Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy
Immutep S.A.S. n=849
NCT06304857 RECRUITING
CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL
4th Military Clinical Hospital with Polyclinic, Poland n=188
NCT06711185 RECRUITING
Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy
University of Campinas, Brazil n=80
NCT05440149 RECRUITING
The Postoperative Radiotherapy in N1 Breast Cancer Patients
Seoul National University Hospital n=1,106
NCT06143553 RECRUITING
Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
Shanghai Yizhong Pharmaceutical Co., Ltd. n=168
NCT06044623 RECRUITING
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
Region Örebro County n=495
NCT06611514 NOT YET RECRUITING
Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer
European Institute of Oncology n=95
NCT06407401 NOT YET RECRUITING
Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC n=399
NCT05063136 RECRUITING
Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer
Henan Cancer Hospital n=1,979
NCT06637150 ACTIVE NOT RECRUITING
Dalpicilib-Enhanced Vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer
Fudan University n=1,388
NCT06612814 ACTIVE NOT RECRUITING
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Zhimin Shao n=307
NCT04547907 RECRUITING
A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
Henan Cancer Hospital n=688
NCT06559696 RECRUITING
Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy
Fujian Medical University Union Hospital n=722
NCT06561607 NOT YET RECRUITING
A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=542
NCT04842617 ACTIVE NOT RECRUITING
Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative
Jiangsu HengRui Medicine Co., Ltd. n=5,274
NCT03755739 RECRUITING
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University n=200
NCT06447623 RECRUITING
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
Fudan University n=184
NCT02344472 ACTIVE NOT RECRUITING
Detect V / CHEVENDO (Chemo vs. Endo)
Prof. Wolfgang Janni n=271
NCT02441933 ACTIVE NOT RECRUITING
Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)
Yonsei University n=878
NCT04540692 RECRUITING
Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer
Latin American Cooperative Oncology Group n=444
NCT05077449 ACTIVE NOT RECRUITING
A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer
Xuanzhu Biopharmaceutical Co., Ltd. n=300
NCT06341621 RECRUITING
Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib
Fudan University n=1,900
NCT01996267 ACTIVE NOT RECRUITING
Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2
The Netherlands Cancer Institute n=437
NCT05861830 RECRUITING
Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)
Peking Union Medical College Hospital n=80
NCT03595592 ACTIVE NOT RECRUITING
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
Fondazione Michelangelo n=650
NCT06270355 NOT YET RECRUITING
Stockholm Mammography Risk Stratified Trial
Karolinska Institutet n=70,000
NCT06278870 RECRUITING
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=312
NCT06268652 RECRUITING
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
Sun Yat-sen University n=302
NCT06268327 NOT YET RECRUITING
Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy
Assiut University n=30
NCT05891093 RECRUITING
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Fudan University n=766
NCT05159193 RECRUITING
Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=372
NCT02641847 ACTIVE NOT RECRUITING
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature
Fudan University n=503
NCT06214195 RECRUITING
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
Zhejiang Cancer Hospital n=276
NCT05954442 RECRUITING
Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
Fudan University n=203
NCT05993559 NOT YET RECRUITING
Necessity of Post-mastectomy Radiotherapy After Neoadjuvant Chemotherapy and Mastectomy
Gangnam Severance Hospital n=1,314
NCT05328258 RECRUITING
Use of GnRHa During Chemotherapy for Fertility Protection
Kenny Rodriguez-Wallberg n=500
NCT03324932 ACTIVE NOT RECRUITING
Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer
Kyoto Prefectural University of Medicine n=160
NCT02221999 ACTIVE NOT RECRUITING
Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients
RenJi Hospital n=250
NCT04722692 RECRUITING
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
Uppsala University n=500
NCT05814354 RECRUITING
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
Jiangsu HengRui Medicine Co., Ltd. n=530
NCT05430399 RECRUITING
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University n=349
NCT05883852 RECRUITING
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
Fudan University n=1,406
NCT05904964 RECRUITING
Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=288
NCT05901428 RECRUITING
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
Fudan University n=1,736
NCT05901935 NOT YET RECRUITING
DP303c in Patients With HER2-positive Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=420
NCT05889871 NOT YET RECRUITING
A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer
Fudan University n=916
NCT05851014 RECRUITING
A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Genor Biopharma Co., Ltd. n=350
NCT05841381 NOT YET RECRUITING
Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer
Fudan University n=876
NCT05212454 RECRUITING
Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks
Second Affiliated Hospital, School of Medicine, Zhejiang University n=400
NCT05804916 RECRUITING
Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer
Peking Union Medical College Hospital n=556
NCT04803539 RECRUITING
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=260
NCT03150576 RECRUITING
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
Cambridge University Hospitals NHS Foundation Trust n=780
NCT01646034 ACTIVE NOT RECRUITING
High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer
The Netherlands Cancer Institute n=74
NCT01057069 ACTIVE NOT RECRUITING
Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer
The Netherlands Cancer Institute n=310
NCT04263298 RECRUITING
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
Herui Yao n=210
NCT03829553 RECRUITING
Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment
Ruijin Hospital n=801
NCT04079049 RECRUITING
BreCLIM-2 - A RCT Investigating Local Treatment for Breast Cancer Liver Metastases
Umeå University n=200
NCT02062489 RECRUITING
Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=688
NCT05253170 NOT YET RECRUITING
Hypo Versus Conventional Fractionation in Reconstructed-Breast Cancer Mastectomy Patients
Seoul National University Bundang Hospital n=622
NCT05172518 NOT YET RECRUITING
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University n=512
NCT02535221 RECRUITING
Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer
Peking University n=234
NCT05059379 RECRUITING
Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer
Fudan University n=1,650
NCT04973319 NOT YET RECRUITING
Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy
Shengjing Hospital n=450
NCT04137653 RECRUITING
Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT
Shengjing Hospital n=1,498
NCT03417622 RECRUITING
Wide Margin vs. Narrow Margin in Postneoadjuvant Lumpectomy
Mansoura University n=370
NCT04736589 NOT YET RECRUITING
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
Peking Union Medical College n=270
NCT04601116 RECRUITING
The MASTER Study (MAmmary Cancer STatin ER Positive Study)
Aarhus University Hospital n=3,360
NCT04646759 RECRUITING
Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=516
NCT02568839 ACTIVE NOT RECRUITING
Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer
Thomas Hatschek n=202
NCT02338310 ACTIVE NOT RECRUITING
Trial of Perioperative Endocrine Therapy - Individualising Care
Institute of Cancer Research, United Kingdom n=4,486
NCT03561740 RECRUITING
A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients
Sun Yat-sen University n=794
NCT01185132 RECRUITING
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
Rocky Mountain Cancer Centers n=660
NCT07593846 NOT YET RECRUITING
The Comparison Between DEDTI BR and T/E BR
West China Hospital n=412
NCT06671912 SUSPENDED
Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial
Alliance for Clinical Trials in Oncology n=1,156
NCT03794388 COMPLETED
Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery
Institut Cancerologie de l'Ouest n=140
NCT02364557 COMPLETED
Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
NRG Oncology n=129
NCT04732598 COMPLETED
A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer
Japanese Foundation for Cancer Research n=281
NCT02525211 TERMINATED
Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment
Institut Paoli-Calmettes n=59
NCT02311959 COMPLETED
Therapeutic Nipple Sparing Mastectomy.
Institut Claudius Regaud n=450
NCT05375461 COMPLETED
TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=293
NCT00893061 COMPLETED
Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer
Centre Oscar Lambret n=44
NCT01613482 TERMINATED
TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention
Centre Oscar Lambret n=13
NCT06038539 TERMINATED
Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Biocon Biologics UK Ltd n=55
NCT01480869 COMPLETED
Study of Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients
Institut du Cancer de Montpellier - Val d'Aurelle n=215
NCT03077841 SUSPENDED
Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer
M.D. Anderson Cancer Center n=928
NCT02767661 COMPLETED
Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer
Sun Yat-sen University n=263
NCT01602380 COMPLETED
A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.
AstraZeneca n=462
NCT03523585 COMPLETED
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Daiichi Sankyo n=608
NCT04024462 COMPLETED
A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer
Hoffmann-La Roche n=200
NCT02000622 COMPLETED
Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
AstraZeneca n=302
NCT03063073 COMPLETED
Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block
South Egypt Cancer Institute n=60
NCT06585969 WITHDRAWN
A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer
Danish Breast Cancer Cooperative Group
NCT05415215 COMPLETED
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
Hoffmann-La Roche n=346
NCT06009627 COMPLETED
Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients
Tianjin Medical University Cancer Institute and Hospital n=119
NCT01413269 COMPLETED
Randomized Study of Hypofractionated and Conventional Fractionation Radiotherapy After Breast Conservative Surgery
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=720
NCT03199885 COMPLETED
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
National Cancer Institute (NCI) n=190
NCT00757302 COMPLETED
Intraoperative Gamma Camera for Breast Cancer Surgery
University Hospital, Strasbourg, France n=110
NCT05114720 COMPLETED
Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer
Sun Yat-sen University n=559
NCT01358877 COMPLETED
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
Hoffmann-La Roche n=4,804
NCT07092475 WITHDRAWN
The Impact of Intraoperative Methadone on Postoperative Opioid Use
University of Utah
NCT01349842 COMPLETED
Circulating Tumor Cells to Guide Chemotherapy for Metastatic Breast Cancer
Institut Curie n=265
NCT03079011 COMPLETED
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
UNICANCER n=1,017
NCT06884254 WITHDRAWN
Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.
EirGenix, Inc.
NCT03598712 TERMINATED
Local Compression Seroma DIminution Objective (CLODIS)
Centre Francois Baclesse n=60
NCT03264547 COMPLETED
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
Japan Breast Cancer Research Group n=446
NCT03367572 COMPLETED
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
University of Rochester NCORP Research Base n=1,363
NCT02839473 COMPLETED
Hydrosorb® Versus Control in the Management of Radio-induced Skin Toxicity: Multicentre Controlled Phase III Randomized Trial
Institut Curie n=278
NCT05128773 TERMINATED
Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity
Sanofi n=3
NCT03778931 COMPLETED
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Stemline Therapeutics, Inc. n=478
NCT04478266 TERMINATED
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
Sanofi n=1,068
NCT02514681 COMPLETED
A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer
Japan Breast Cancer Research Group n=226
NCT01805076 COMPLETED
MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
Alliance for Clinical Trials in Oncology n=317
NCT04815083 TERMINATED
Fluorescence Imaging of Carcinoma During Breast Conserving Surgery
SBI ALApharma Canada, Inc. n=57
NCT04862585 COMPLETED
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
Ohio State University Comprehensive Cancer Center n=130
NCT00770809 COMPLETED
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI) n=305
NCT06597175 COMPLETED
Evaluating Investigational Medical Device for Breast Tumor Diagnosis Using Diffusion Optical Spectroscopy
Olive Healthcare n=300
NCT04740918 TERMINATED
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
Hoffmann-La Roche n=96
NCT02003209 COMPLETED
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
National Cancer Institute (NCI) n=315
NCT01772472 COMPLETED
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Hoffmann-La Roche n=1,486
NCT01275677 COMPLETED
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
National Cancer Institute (NCI) n=3,270
NCT01354522 COMPLETED
TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer
Peking Union Medical College Hospital n=204
NCT04588246 TERMINATED
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology n=19
NCT00601900 COMPLETED
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
National Cancer Institute (NCI) n=394
NCT04973930 SUSPENDED
Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer
New York State Psychiatric Institute n=20
NCT01526369 COMPLETED
A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer
Cancer Trials Ireland n=75
NCT04174599 COMPLETED
Study to Compare the Efficacy and Safety of F-627 and GRAN®
EVIVE Biotechnology n=242
NCT03753776 COMPLETED
Phase III Trial Evaluating Radium Bromatum Homeopathic Treatment Efficacy on Radiodermatitis Prevention and Treatment for Breast Cancer Women
Centre Hospitalier Universitaire de Saint Etienne n=232
NCT01779206 COMPLETED
ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
West German Study Group n=4,936
NCT04193722 COMPLETED
The Effect of Hyperbaric OxygeN Therapy on brEast Cancer Patients With Late Radiation toxicitY - UMBRELLA HONEY Trial
UMC Utrecht n=189
NCT00667251 COMPLETED
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
Novartis Pharmaceuticals n=652
NCT02492711 COMPLETED
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
MacroGenics n=624
NCT01958021 COMPLETED
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer
Novartis Pharmaceuticals n=668
NCT02214381 COMPLETED
A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response
West German Study Group n=80
NCT01781338 COMPLETED
Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
West German Study Group n=4,936
NCT02163694 COMPLETED
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
AbbVie n=513
NCT03936933 TERMINATED
Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer
Eurofarma Laboratorios S.A. n=6
NCT02437318 COMPLETED
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
Novartis Pharmaceuticals n=572
NCT00949598 COMPLETED
Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer
Institut du Cancer de Montpellier - Val d'Aurelle n=177
NCT01084876 COMPLETED
Demonstrate Efficacy and Safety of Metastatic Breast Cancer
Celltrion n=475
NCT01573442 COMPLETED
Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
Alliance for Clinical Trials in Oncology n=227
NCT04109066 COMPLETED
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
Bristol-Myers Squibb n=521
NCT02883361 WITHDRAWN
Motivational Enhancement Therapy to Improve Adherence to Aromatase Inhibitors
University of Calgary
NCT03013504 COMPLETED
A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients
Prestige Biopharma Limited n=503
NCT03726879 COMPLETED
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
Hoffmann-La Roche n=454
NCT03901339 COMPLETED
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer
Gilead Sciences n=543
NCT05054751 COMPLETED
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
Genor Biopharma Co., Ltd. n=275
NCT01224678 COMPLETED
Vitamin D and Breast Cancer Biomarkers in Female Patients
Alliance for Clinical Trials in Oncology n=300
NCT02028507 COMPLETED
Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors
Spanish Breast Cancer Research Group n=693
NCT02037529 SUSPENDED
Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
Academic and Community Cancer Research United n=201
NCT04395339 TERMINATED
GM1 Prophylaxis for WBRT Related Cognitive Dysfunction
Sun Yat-sen University n=51
NCT05239663 TERMINATED
GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer
Sun Yat-sen University n=76
NCT04799249 COMPLETED
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
G1 Therapeutics, Inc. n=194
NCT03439046 COMPLETED
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant
Novartis Pharmaceuticals n=287
NCT05283837 COMPLETED
A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)
Zydus Lifesciences Limited n=268
NCT00673335 COMPLETED
Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation
UNICANCER n=170
NCT03493854 COMPLETED
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
Hoffmann-La Roche n=500
NCT01619111 COMPLETED
DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs
Prof. Wolfgang Janni n=105
NCT05207514 TERMINATED
Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer
Samyang Biopharmaceuticals Corporation n=26
NCT03084237 COMPLETED
Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer
Shanghai Henlius Biotech n=652
NCT03324802 COMPLETED
Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After Surgery
Mayo Clinic n=107
NCT05629949 COMPLETED
A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer
Qilu Pharmaceutical Co., Ltd. n=474
NCT04629846 COMPLETED
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.
Qilu Pharmaceutical Co., Ltd. n=517
NCT01942135 COMPLETED
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
Pfizer n=521
NCT02278120 COMPLETED
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Novartis Pharmaceuticals n=672
NCT03337724 COMPLETED
A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Hoffmann-La Roche n=579
NCT01822314 COMPLETED
Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer
Fondazione Michelangelo n=632
NCT02620280 COMPLETED
Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1
Fondazione Michelangelo n=278
NCT01120184 COMPLETED
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
Hoffmann-La Roche n=1,095
NCT05338723 COMPLETED
Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients
Tanta University n=50
NCT05065411 TERMINATED
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer
Veru Inc. n=5
NCT05474690 WITHDRAWN
A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer
Henan Cancer Hospital
NCT03265574 COMPLETED
PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?
South Tees Hospitals NHS Foundation Trust n=111
NCT04869943 TERMINATED
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
Veru Inc. n=52
NCT05189535 COMPLETED
"Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"
Ain Shams University n=66
NCT03989037 COMPLETED
A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer
Shanghai Institute Of Biological Products n=580
NCT01864746 COMPLETED
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
GBG Forschungs GmbH n=1,250
NCT02422615 COMPLETED
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.
Novartis Pharmaceuticals n=726
NCT04239716 COMPLETED
Regional Anesthesia for Modified Radical Mastectomy With Axillary Lymph Node Dissection
Tanta University n=13
NCT05503108 SUSPENDED
Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer
Leiden University Medical Center n=10
NCT03786094 TERMINATED
Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Spexis AG n=432
NCT02941926 COMPLETED
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
Novartis Pharmaceuticals n=3,246
NCT03262935 COMPLETED
SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
Byondis B.V. n=437
NCT02068092 COMPLETED
Olive Oil for High Risk Breast Cancer Prevention in Women
The Methodist Hospital Research Institute n=51
NCT03200704 COMPLETED
A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer
Novadaq Technologies ULC, now a part of Stryker n=152
NCT01101438 COMPLETED
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer
Canadian Cancer Trials Group n=3,649
NCT01303679 TERMINATED
1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
ARCAGY/ GINECO GROUP n=117
NCT04385433 TERMINATED
A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer
Institut du Cancer de Montpellier - Val d'Aurelle n=15
NCT03686215 COMPLETED
Investigation of Novel Surgical Imaging for Tumor Excision
Lumicell, Inc. n=406
NCT04822597 COMPLETED
Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer
University of Wisconsin, Madison n=167
NCT03252431 COMPLETED
Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology n=393
NCT05727098 COMPLETED
Dexmedetomedine and Ketamine in Erector Spinae Block for Postoperative Analgesia Following Mastectomy.
National Cancer Institute, Egypt n=75
NCT03152929 TERMINATED
Paravertebral Block (PVC) Versus Pectoral Nerve Block (PEC)
Corewell Health West n=89
NCT02586025 COMPLETED
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel
Hoffmann-La Roche n=329
NCT05110170 COMPLETED
Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®
Luye Pharma Group Ltd. n=188
NCT04335006 TERMINATED
A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.
Jiangsu HengRui Medicine Co., Ltd. n=80
NCT03084939 COMPLETED
Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche n=351
NCT02915744 COMPLETED
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Nektar Therapeutics n=178
NCT03564171 COMPLETED
Prehabilitation for Women Undergoing Pre-operative Chemotherapy for Breast Cancer
Sunnybrook Health Sciences Centre n=63
NCT02927249 TERMINATED
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
Alliance for Clinical Trials in Oncology n=3,021
NCT01875367 COMPLETED
Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer
Spanish Breast Cancer Research Group n=166
NCT02332928 TERMINATED
Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy
Virginia Commonwealth University n=80
NCT03354611 TERMINATED
Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging
Koning Corporation n=21
NCT03969121 COMPLETED
Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
Kyoto Breast Cancer Research Network n=141
NCT05301010 COMPLETED
Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients
Nanogen Pharmaceutical Biotechnology Joint Stock Company n=128
NCT03433313 COMPLETED
Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer
EirGenix, Inc. n=807
NCT03462251 COMPLETED
Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line
iOMEDICO AG n=41
NCT03286842 COMPLETED
To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
AstraZeneca n=256
NCT03294330 COMPLETED
SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer
Milton S. Hershey Medical Center n=35
NCT02997553 COMPLETED
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
Institut de Cancérologie de Lorraine n=744
NCT01598298 COMPLETED
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy
SWOG Cancer Research Network n=299
NCT04554056 COMPLETED
Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF
Mabwell (Shanghai) Bioscience Co., Ltd. n=586
NCT04874935 COMPLETED
The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer
Tanta University n=66
NCT01403779 COMPLETED
Comparison of the Cosmetic Outcome of Hypofractionated Versus Normofractionated IMRT in Treatment of Breast Cancer
Universitätsmedizin Mannheim n=226
NCT04109391 COMPLETED
Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03
Tanvex BioPharma USA, Inc. n=338
NCT05591456 COMPLETED
Accelerated Hypofractionated 1 Week Radiotherapy in Breast Cancer Patients
Zagazig University n=100
NCT00785291 COMPLETED
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
National Cancer Institute (NCI) n=799
NCT02594371 COMPLETED
Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer
Athenex, Inc. n=402
NCT02340221 TERMINATED
A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
Hoffmann-La Roche n=631
NCT02574455 COMPLETED
Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)
Gilead Sciences n=529
NCT01966471 COMPLETED
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
Hoffmann-La Roche n=1,846
NCT01517802 COMPLETED
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
Janssen Research & Development, LLC n=32
NCT01067144 TERMINATED
Stanford Accelerated Recovery Trial (START)
Stanford University n=422
NCT01095003 COMPLETED
Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer
Pierre Fabre Medicament n=770
NCT02546934 COMPLETED
ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)
Fudan University n=254
NCT02336750 COMPLETED
Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis
Fudan University n=212
NCT00887536 COMPLETED
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
NSABP Foundation Inc n=1,613
NCT01702571 COMPLETED
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Hoffmann-La Roche n=2,185
NCT03764943 COMPLETED
Immunonutrition and Carbohydrate Loading Strategies in Breast Reconstruction
University of Wisconsin, Madison n=125
NCT02643420 COMPLETED
SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)
Spectrum Pharmaceuticals, Inc n=406
NCT02953340 COMPLETED
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide
Spectrum Pharmaceuticals, Inc n=237
NCT02472964 COMPLETED
Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.
Mylan Inc. n=500
NCT04951245 COMPLETED
Ultrasound-assisted CNSs Mapping Versus Dual-tracer-guided Sentinel Lymph Node Biopsy
Guangdong Provincial People's Hospital n=330
NCT02600923 COMPLETED
Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate
Pfizer n=131
NCT03556358 COMPLETED
Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer
Tanvex BioPharma USA, Inc. n=809
NCT02482753 COMPLETED
Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer
Chipscreen Biosciences, Ltd. n=365
NCT02896855 COMPLETED
A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Hoffmann-La Roche n=243
NCT00703326 COMPLETED
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
Eli Lilly and Company n=1,144
NCT02468739 COMPLETED
Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer
Sun Yat-sen University n=206
NCT03096847 COMPLETED
Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
Novartis Pharmaceuticals n=502
NCT02692755 COMPLETED
Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer
Georgetown University n=35
NCT01077154 TERMINATED
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Amgen n=4,509
NCT04059809 COMPLETED
Photobiomodulation for Breast Cancer Radiodermatitis
AC Camargo Cancer Center n=48
NCT03326674 TERMINATED
Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC
Odonate Therapeutics, Inc. n=685
NCT03079219 COMPLETED
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients
CCTU n=120
NCT01989676 COMPLETED
A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
Pfizer n=707
NCT04075058 COMPLETED
Hypofractionated Radiation Therapy in Patients With Breast Cancer
Post Graduate Institute of Medical Education and Research, Chandigarh n=1,070
NCT03905343 TERMINATED
Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC
Swiss Cancer Institute n=25
NCT02518191 COMPLETED
Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity
Xiangyun Zong n=345
NCT01808573 COMPLETED
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Puma Biotechnology, Inc. n=621
NCT00878709 COMPLETED
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Puma Biotechnology, Inc. n=2,840
NCT01492101 COMPLETED
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
Nektar Therapeutics n=852
NCT04718324 COMPLETED
PREMs on PROMs in Breast Disease (PREMs_PROMs)
Uppsala University n=230
NCT03658213 WITHDRAWN
To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.
AstraZeneca
NCT02872103 COMPLETED
Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology n=122
NCT04281355 WITHDRAWN
Individualized Locoregional Treatment of Initially Biopsy-proven Node-positive Breast Cancer After Primary Systemic Therapy
Karolinska Institutet
NCT01150513 COMPLETED
Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer
Chinese Academy of Medical Sciences n=320
NCT01690702 COMPLETED
Study of Nab-Paclitaxel in High Risk Early Breast Cancer
GBG Forschungs GmbH n=2,886
NCT02730091 TERMINATED
A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Centre Hospitalier Universitaire de Besancon n=98
NCT02137837 TERMINATED
S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer
SWOG Cancer Research Network n=37
NCT01591811 COMPLETED
Prospective Trial of Two Prone Breast Radiotherapy Techniques With Randomization to Concurrent Versus Weekly Boost
NYU Langone Health n=433
NCT03343145 COMPLETED
A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients
Dong-A ST Co., Ltd. n=143
NCT02511639 COMPLETED
Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients
Istituto Oncologico Veneto IRCCS n=110
NCT03165149 COMPLETED
Effect of a Topical Ketamine on Acute and Chronic Pain, Dose Finding
Assiut University n=90
NCT01940497 COMPLETED
A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Hoffmann-La Roche n=240
NCT04237090 COMPLETED
Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel
Ciusss de L'Est de l'Île de Montréal n=27
NCT00625898 TERMINATED
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
NSABP Foundation Inc n=3,509
NCT01810393 COMPLETED
A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years
Hoffmann-La Roche n=114
NCT01610284 COMPLETED
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Novartis Pharmaceuticals n=1,147
NCT01583426 COMPLETED
Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)
GBG Forschungs GmbH n=1,229
NCT01000662 COMPLETED
Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor
NYU Langone Health n=412
NCT03740945 WITHDRAWN
Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer
EndoCeutics Inc.
NCT01950182 COMPLETED
Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer
Sun Yat-sen University n=392
NCT03050398 TERMINATED
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
Novartis Pharmaceuticals n=8
NCT01112826 COMPLETED
Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer
Sun Yat-sen University n=443
NCT01314833 COMPLETED
Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy
Fudan University n=1,570
NCT04031703 COMPLETED
Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)
Fudan University n=647
NCT01806259 COMPLETED
Ketorolac in Breast Cancer Surgery
Université Catholique de Louvain n=203
NCT03176238 COMPLETED
Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Novartis Pharmaceuticals n=235
NCT02532400 TERMINATED
Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients
Ruijin Hospital n=21
NCT04127019 COMPLETED
Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)
Fudan University n=2,079
NCT02861859 COMPLETED
Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study
Ottawa Hospital Research Institute n=221
NCT01099436 COMPLETED
Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients
Borstkanker Onderzoek Groep n=250
NCT01935492 COMPLETED
8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer
Borstkanker Onderzoek Groep n=420
NCT02961790 COMPLETED
Oxybutynin Chloride in Managing Hot Flashes
Academic and Community Cancer Research United n=150
NCT00600340 COMPLETED
2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
Central European Cooperative Oncology Group n=564
NCT00567190 COMPLETED
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
Genentech, Inc. n=808
NCT01902823 TERMINATED
Effect of Cancer Nurse Navigators on Patient Outcomes
University of Wisconsin, Madison n=16
NCT03811418 WITHDRAWN
A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer
iOMEDICO AG
NCT00536081 COMPLETED
Various G-CSF Regimens to Prevent Infection During Chemotherapy
Academisch Ziekenhuis Maastricht n=172
NCT02126449 COMPLETED
DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer
Leiden University Medical Center n=131
NCT02376985 COMPLETED
Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT
Comprehensive Support Project for Oncology Research n=174
NCT01104935 COMPLETED
National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT]
Comprehensive Support Project for Oncology Research n=275
NCT01591746 COMPLETED
Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction
Mayo Clinic n=131
NCT01856543 COMPLETED
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Memorial Sloan Kettering Cancer Center n=143
NCT01419717 COMPLETED
Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
Amgen n=129
NCT01926886 COMPLETED
A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)
Hoffmann-La Roche n=102
NCT01091168 COMPLETED
Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer
Pierre Fabre Medicament n=594
NCT02402712 COMPLETED
Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer
Hoffmann-La Roche n=418
NCT02672189 COMPLETED
Internet-based Cognitive Behavioral Therapy for Breast Cancer Patients With Climacteric Symptoms
The Netherlands Cancer Institute n=254
NCT02091765 COMPLETED
RCT of an Internet-based CBT Program for Sexuality and Intimacy Problems in Women Treated for Breast Cancer
The Netherlands Cancer Institute n=160
NCT02040935 COMPLETED
A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants
Hoffmann-La Roche n=128
NCT01049425 COMPLETED
Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer
West German Study Group n=3,198
NCT01901146 COMPLETED
Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer
Amgen n=725
NCT01644890 COMPLETED
A Phase III Study of NK105 in Patients With Breast Cancer
Nippon Kayaku Co., Ltd. n=436
NCT03997188 COMPLETED
Zinc-L-Carnosine Prevents Dysphagia in Breast Cancer Patients Undergoing Adjuvant Radiotherapy
Cynthia Aristei n=40
NCT02995772 COMPLETED
Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients
Dharmais National Cancer Center Hospital n=122
NCT01645839 COMPLETED
Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer
Centre Oscar Lambret n=74
NCT02194166 COMPLETED
A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration
Hoffmann-La Roche n=90
NCT02311543 COMPLETED
Impact of a Surgical Sealing Patch on Lymphatic Drainage After ALND for Breast Cancer
Swiss Cancer Institute n=142
NCT00992706 COMPLETED
F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer
Swiss Cancer Institute n=91
NCT01131195 COMPLETED
Metronomic Therapy in Metastatic Breast Cancer.
Swiss Cancer Institute n=139
NCT00776724 COMPLETED
Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm
National Taiwan University Hospital n=166
NCT02253459 COMPLETED
Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer
Beijing Biostar Pharmaceuticals Co., Ltd. n=405
NCT01964391 COMPLETED
A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
Hoffmann-La Roche n=174
NCT01881230 COMPLETED
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Celgene n=191
NCT01376349 COMPLETED
Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms
Alliance for Clinical Trials in Oncology n=464
NCT01633060 TERMINATED
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Novartis Pharmaceuticals n=432
NCT03240224 COMPLETED
Bioinformation Therapy for Breast Cancer
Fuda Cancer Hospital, Guangzhou n=120
NCT01663727 COMPLETED
Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer
Hoffmann-La Roche n=481
NCT02187744 COMPLETED
A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)
Pfizer n=226
NCT00876395 COMPLETED
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Novartis Pharmaceuticals n=719
NCT01073865 COMPLETED
Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer
AstraZeneca n=222
NCT01764022 COMPLETED
A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients
Biocad n=225
NCT01234337 COMPLETED
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Bayer n=537
NCT02149524 COMPLETED
A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer
Samsung Bioepis Co., Ltd. n=875
NCT02929576 WITHDRAWN
Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer
Pfizer
NCT00793962 COMPLETED
A Phase Ⅲ Randomized Clinical Trial of Postmastectomy Hypofractionation Radiotherapy in High-risk Breast Cancer
Chinese Academy of Medical Sciences n=810
NCT00639106 COMPLETED
Tissue Expander/Implant Reconstruction: A Single-Blinded, Randomized, Controlled Trial
Memorial Sloan Kettering Cancer Center n=70
NCT01638247 COMPLETED
Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
GBG Forschungs GmbH n=56
NCT02019277 COMPLETED
A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Hoffmann-La Roche n=50
NCT02225470 COMPLETED
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Eisai Co., Ltd. n=530
NCT01035268 TERMINATED
Adipose Tissue Transfer for Moderate Breast Cancer Conservative Treatment Sequella
Institut Claudius Regaud n=196
NCT01026142 COMPLETED
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
Hoffmann-La Roche n=452
NCT01942980 COMPLETED
Evaluation of the Efficacy of Hippocampal Avoidance on the Cognitive Toxicity of Whole-Brain Radiation Therapy After Surgical Resection of Single Brain Metastasis of Breast Cancer
Institut Paoli-Calmettes n=8
NCT01796444 WITHDRAWN
Axillary Lymph Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node
Shandong Cancer Hospital and Institute
NCT01668914 COMPLETED
Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Positive
Shandong Cancer Hospital and Institute n=126
NCT02269696 WITHDRAWN
The Effect of Metoprolol on Anaesthesia, the Need for Analgesics, and Pain in Breast Cancer Patients
Kuopio University Hospital
NCT03081234 WITHDRAWN
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer
Novartis Pharmaceuticals
NCT01792999 COMPLETED
Koning Breast CT for Breast Imaging in China
Koning (Tianjin) Medical Equipment Co., Ltd n=418
NCT03202446 TERMINATED
Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer
Eske Corporation S.A.C n=18
NCT02784730 WITHDRAWN
Iterative PICC Placement Versus Long Term Device
Centre Leon Berard
NCT01724450 COMPLETED
Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity
University of Sao Paulo n=200
NCT00950300 COMPLETED
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
Hoffmann-La Roche n=596
NCT01655992 TERMINATED
A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)
Fudan University n=386
NCT03381417 COMPLETED
Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.
Nanogen Pharmaceutical Biotechnology Joint Stock Company n=128
NCT01724242 WITHDRAWN
Vaginal DHEA for Women After Breast Cancer
Hadassah Medical Organization
NCT02980965 COMPLETED
Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer
Fudan University n=249
NCT02483767 COMPLETED
Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer
Peking Union Medical College Hospital n=98
NCT02768714 WITHDRAWN
Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy
Eurofarma Laboratorios S.A.
NCT00684216 TERMINATED
Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
The Netherlands Cancer Institute n=10
NCT01516736 COMPLETED
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Sandoz n=308
NCT02001506 COMPLETED
Neoadjuvant Chemotherapy of 6 Cycles vs 8 Cycles in Node Positve Breast Cancer
Asan Medical Center n=250
NCT01712893 COMPLETED
Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer
Fudan University n=216
NCT01495650 COMPLETED
Effect of a Tailored Program of Physical Activity and Nutritional Counseling on Fatigue Reduction in Breast Cancer Patients Receiving an Adjuvant Treatment
Institut du Cancer de Montpellier - Val d'Aurelle n=240
NCT00775645 COMPLETED
S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo
SWOG Cancer Research Network n=437
NCT00981305 COMPLETED
Impact of Lactate-Containing Vaginal Lubricant on Sexual Dysfunction in Young Breast Cancer Survivors
Seoul National University Hospital n=136
NCT02286778 COMPLETED
Eradication of Malignant Carcinoma in the Breast Tissue
Optimal Health Research n=60
NCT02125344 COMPLETED
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
GBG Forschungs GmbH n=961
NCT02651610 WITHDRAWN
Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
Peregrine Pharmaceuticals
NCT00789581 COMPLETED
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
SCRI Development Innovations, LLC n=614
NCT00685256 COMPLETED
Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children
Georgetown University n=245
NCT00863655 COMPLETED
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Novartis Pharmaceuticals n=724
NCT00876486 COMPLETED
Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer
Samyang Biopharmaceuticals Corporation n=213
NCT01539317 COMPLETED
Therapy to Prevent Sexual Pain in Breast Cancer Survivors
OHSU Knight Cancer Institute n=50
NCT01385137 COMPLETED
S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy
SWOG Cancer Research Network n=262
NCT01007942 COMPLETED
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
Novartis Pharmaceuticals n=569
NCT00956813 COMPLETED
Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy
Alliance for Clinical Trials in Oncology n=210
NCT01331629 COMPLETED
Impact of Art Therapy on Fatigue and Quality of Life of Patients Treated With Adjuvant Radiotherapy for Breast Cancer
Centre Francois Baclesse n=322
NCT01572727 COMPLETED
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Novartis Pharmaceuticals n=416
NCT01762020 COMPLETED
Barrier Film vs. Standard Skin Care in Preventing Dermatitis in Women With Breast Cancer Receiving Radiation
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's n=56
NCT02144012 TERMINATED
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer
Hoffmann-La Roche n=49
NCT01479244 COMPLETED
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Galena Biopharma, Inc. n=758
NCT01626222 COMPLETED
4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer
Novartis Pharmaceuticals n=301
NCT02213744 TERMINATED
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
Merrimack Pharmaceuticals n=113
NCT01708798 TERMINATED
Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer
University of British Columbia n=44
NCT02609321 COMPLETED
Efficacy of Thoracic Paravertebral Block in the Reduction of Acute Post-surgical Pain in Patients With Breast Cancer
Instituto de Cancerología S.A. n=60
NCT01986569 COMPLETED
Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer
Asan Medical Center n=93
NCT00912444 TERMINATED
Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer
Shanghai Jiao Tong University School of Medicine n=102
NCT00661102 COMPLETED
A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
Hoffmann-La Roche n=598
NCT00829166 COMPLETED
A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche n=991
NCT01419197 COMPLETED
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy
Hoffmann-La Roche n=602
NCT01246427 COMPLETED
Evaluation of Homeopathic Treatment for Hot Flashes in Non Metastatic Breast Cancer
Centre Leon Berard n=138
NCT00868634 COMPLETED
Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer
iOMEDICO AG n=600
NCT01413828 COMPLETED
Trastuzumab Administered Concurrently or Sequentially to Anthracycline-containing Adjuvant Regimen for Breast Cancer
Peking Union Medical College Hospital n=201
NCT00692458 WITHDRAWN
A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)
Merck Sharp & Dohme LLC
NCT00805597 TERMINATED
Clinical Trial of Postmastectomy Radiotherapy in Breast Cancer With One to Three Positive Nodes
Chinese Academy of Medical Sciences n=40
NCT01568346 TERMINATED
Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy
Dana-Farber Cancer Institute n=9
NCT00702949 COMPLETED
Pregabalin in Treating Women With Hot Flashes
Alliance for Clinical Trials in Oncology n=207
NCT00249015 COMPLETED
Trial of Combined Aerobic and Resistance Exercise in Breast Cancer Survivors
AHS Cancer Control Alberta n=301
NCT02112149 COMPLETED
Effect of the LIVESTRONG at the YMCA Exercise Program on Cancer Related Outcomes in Cancer Survivors
Yale University n=200
NCT02794324 COMPLETED
The HeartSpare Study (Stage I)
Royal Marsden NHS Foundation Trust n=57
NCT01001728 COMPLETED
SuPr Study (Supine Versus Prone Treatment Position in Breast Radiotherapy)
Royal Marsden NHS Foundation Trust n=25
NCT02620371 COMPLETED
Efficacy of Ketamine Added to Local Anesthetic in Modified Pectoral Block for Management of Postoperative Pain
Assiut University n=60
NCT01530607 COMPLETED
Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
King Faisal Specialist Hospital & Research Center n=416
NCT01426880 COMPLETED
Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
GBG Forschungs GmbH n=595
NCT01250379 COMPLETED
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)
Hoffmann-La Roche n=494
NCT01773460 TERMINATED
Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane
GBG Forschungs GmbH n=3
NCT01204437 COMPLETED
Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast
GBG Forschungs GmbH n=400
NCT00998738 TERMINATED
Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer
Mayo Clinic n=1
NCT01112254 COMPLETED
Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris n=360
NCT02539615 WITHDRAWN
A Trial of the ForeCYTE Breast Aspirator for Cytological Testing of Nipple Aspirate Fluid in Women 30-55 Years Old
Atossa Therapeutics, Inc.
NCT02058615 COMPLETED
Feasibility Testing and Evaluation of an Online Toolkit for Male Spouses of Women With Breast Cancer
University of Alberta n=57
NCT01546649 COMPLETED
A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer
Takeda n=167
NCT00902330 COMPLETED
Cranial Stimulation for Chemotherapy Symptoms in Breast Cancer
Virginia Commonwealth University n=161
NCT01809171 TERMINATED
Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients
Universitaire Ziekenhuizen KU Leuven n=15
NCT01688479 COMPLETED
Trial Comparing Calendula Officinalis With Aqueous Cream "Essex" to Treat Skin Reactions From Radiotherapy of Breast Cancer
Karolinska University Hospital n=420
NCT01281904 COMPLETED
Acupressure for Persistent Cancer Related Fatigue
University of Michigan n=288
NCT01548534 TERMINATED
A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer
University Hospital, Tours n=65
NCT00990977 COMPLETED
Mindfulness and Cancer Mamma - Clinical Trial MBSR Among Women Operated for Breast Cancer
Danish Cancer Society n=336
NCT01344967 COMPLETED
Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Patients With Metastatic Breast Cancer: Duration of Effect
University Health Network, Toronto n=21
NCT01519700 COMPLETED
Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim
Sandoz n=218
NCT01300351 COMPLETED
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women
AstraZeneca n=249
NCT02408107 COMPLETED
A Home-based Physical Activity Intervention in Breast Cancer Survivors
Dudley Group NHS Foundation Trust n=80
NCT01287624 COMPLETED
Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)
Fudan University n=240
NCT00929240 COMPLETED
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
Hoffmann-La Roche n=287
NCT02314806 COMPLETED
Gentamicin Versus Clindamycin Versus Normal Saline Lavage in Axilla
Hospital General Universitario Elche n=51
NCT01104584 COMPLETED
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
Bayer n=460
NCT01067976 COMPLETED
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI
Bayer n=446
NCT00925548 TERMINATED
STRIDE - STimulating Immune Response In aDvanced brEast Cancer
EMD Serono n=16
NCT01142479 COMPLETED
Compound Herbal Formula (TPE-1) for Leukopenia and Cancer-related Fatigue in Breast Cancer Patients With Radiotherapy
Taipei City Hospital n=60
NCT01459003 COMPLETED
Evaluation of Beauty Care Before Chemotherapy in Women With Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris n=400
NCT01355523 TERMINATED
The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients
Melissa Voigt Hansen n=54
NCT02109068 COMPLETED
Lifestyle, Exercise and Nutrition Study 1
Yale University n=100
NCT00852683 COMPLETED
The Effects of Peri-Operative Pregabalin on Post-Operative Pain Following Breast Cancer Surgery With Axillary Node Dissection: A Pilot Study
Nova Scotia Health Authority n=70
NCT00950911 COMPLETED
Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
Amgen n=35
NCT01392586 TERMINATED
Systemic Therapy With or Without Upfront Surgery in Metastatic Breast Cancer
Jeroen Bosch Ziekenhuis n=10
NCT00859703 COMPLETED
Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer
Hospices Civils de Lyon n=20
NCT00938652 COMPLETED
A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer
Sanofi n=519
NCT00963729 COMPLETED
Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery
Imperial College London n=756
NCT00711529 COMPLETED
Pilot Study Comparing Hypnotherapy and Gabapentin for Hot Flashes.
Women and Infants Hospital of Rhode Island n=27
NCT00671918 COMPLETED
Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma
Navidea Biopharmaceuticals n=186
NCT01106040 COMPLETED
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Navidea Biopharmaceuticals n=163
NCT00869674 TERMINATED
GeneSearch™ Breast Lymph Node (BLN) Assay China Registration Study
Johnson & Johnson Medical, China n=540
NCT01200212 TERMINATED
A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer
GBG Forschungs GmbH n=432
NCT01433562 COMPLETED
Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients
Dexa Medica Group n=40
NCT01611051 COMPLETED
A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy
Jiangsu HengRui Medicine Co., Ltd. n=330
NCT01079676 COMPLETED
A Non-inferiority Study Comparing Two Filgrastim Preparations in Breast Cancer
Eurofarma Laboratorios S.A. n=220
NCT00917748 COMPLETED
Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)
Sanofi n=84
NCT01587248 COMPLETED
Use of Harmonic in Breast Surgery
Aga Khan University n=152
NCT00670878 COMPLETED
Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer
Ludwig-Maximilians - University of Munich n=799
NCT01180335 COMPLETED
Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris n=303
NCT00911456 COMPLETED
Can 3D Ultrasound Be Used Reproducibly by Radiation Therapists in Partial Breast Image-Guided Radiation Therapy
British Columbia Cancer Agency n=27
NCT00539474 COMPLETED
"The Efficacy of 'Radioguided Occult Lesion Localization' (ROLL) Versus 'Wire-guided Localization' (WGL) in Breast Conserving Surgery for Non-palpable Breast Cancer: a Randomized Clinical Trial"
UMC Utrecht n=316
NCT00645138 COMPLETED
Comparison of Paravertebral Block With General Anesthesia in Patients Undergoing Breast Cancer Surgery
Weill Medical College of Cornell University n=40
NCT00942396 WITHDRAWN
Study to Compare the Diagnostic Accuracy of Nuance Full-Field Digital Mammography to Screen-Film Mammography
Planmed Oy n=250
NCT01108016 COMPLETED
Expanding Rural Access: Distance Delivery of Support Groups (Main Study)
Stanford University n=100
NCT07590505 COMPLETED
Ultrahypofractionated Versus Normofractionated Sequential Boost After Whole-breast Radiation Therapy in Patients Treated With Breast-conserving Surgery for Breast Cancer
Cancer Research Antwerp n=132

Full Breast Cancer Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only